whatshot

RGBPP   $10.499948  0.0 Market Closed

show_chart Advanced Chart of RGBPP
Last Events:

2023-02-14 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: exit from the overbought zone.

2023-02-11 Trend pattern changed from расширяющийся канал to канал.

2023-02-10 Trend pattern changed from не определен to расширяющийся канал.

2023-02-10 Signal in Stochastic changed from не определен to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-02-10 Signal in MACD changed from не определен to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: main and signal line crossing.

2023-02-10 Signal in RSI changed from не определен to bearish recovery. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-02-10 Signal in EMA100 changed from не определен to bearish reversal. 2023-01-11 the price crossed down the moving average line and formed a short-term downside trend.

2023-02-10 Signal in EMA50 changed from не определен to bearish reversal. 2023-01-11 the price crossed down the moving average line and demonstrates a strong downside trend.

Current temperature: 0.00
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd Sell Sell -
stoch Sell Sell Sell
ma20 - - -
ma50 - - -
ma100 Sell - -
Candlestick PatternMarch 2, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US75886M2017
ceo Dr. David Raymond Koos DBA, Ph.D.
Website https://regenbiopharmainc.com
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. The company was incorporated in 2012 and is based in La Mesa, California.